CYTK
NASDAQ
$79.11
Cytokinetics Inc (CYTK)
Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering, developing and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $107.80 (+36.27%)
Market Cap
$10B
EPS 5Y CAGR
+27.73%
FCF 5Y CAGR
+138.74%
Free Cash Flow Yield
-5.39%
Price Chart
Valuation
Market Cap$10B
Forward P/E117.65
P/S105.12
P/B60.31
Profitability
Total Revenue (TTM)$106M
Gross Profit (TTM)-$308M
EBITDA-$735M
Operating Margin-949%
EPS-$6.84
Financial Health
Debt-to-Equity-155.9%
Free Cash Flow Yield-5.39%
Growth & Risk
EPS 5Y CAGR+27.73%
Revenue 5Y CAGR+12.56%
FCF 5Y CAGR+138.74%
Beta (5Y)0.77
Sharpe Ratio1.38